* FDA accepts BLA for BioMarin’s Cerliponase Alfa for CLN2
disease, form of Batten disease
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
The post BRIEF-FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease appeared first on NASDAQ.